RÉSUMÉ
Carbapenems are considered last-resort antibiotics for the treatment of infections caused by multidrug-resistant Enterobacterales, but carbapenem resistance due to acquisition of carbapenemase genes is a growing threat that has been reported worldwide. Klebsiella pneumoniae carbapenemase (blaKPC) is the most common type of carbapenemase in Canada and elsewhere; it can hydrolyze penicillins, cephalosporins, aztreonam, and carbapenems and is frequently found on mobile plasmids in the Tn4401 transposon. This means that alongside clonal expansion, blaKPC can disseminate through plasmid- and transposon-mediated horizontal gene transfer. We applied whole genome sequencing to characterize the molecular epidemiology of 829 blaKPC carbapenemase-producing isolates collected by the Canadian Nosocomial Infection Surveillance Program from 2010 to 2021. Using a combination of short-read and long-read sequencing, we obtained 202 complete and circular blaKPC-encoding plasmids. Using MOB-suite, 10 major plasmid clusters were identified from this data set which represented 87% (175/202) of the Canadian blaKPC-encoding plasmids. We further estimated the genomic location of incomplete blaKPC-encoding contigs and predicted a plasmid cluster for 95% (603/635) of these. We identified different patterns of carbapenemase mobilization across Canada related to different plasmid clusters, including clonal transmission of IncF-type plasmids (108/829, 13%) in K. pneumoniae clonal complex 258 and novel repE(pEh60-7) plasmids (44/829, 5%) in Enterobacter hormaechei ST316, and horizontal transmission of IncL/M (142/829, 17%) and IncN-type plasmids (149/829, 18%) across multiple genera. Our findings highlight the diversity of blaKPC genomic loci and indicate that multiple, distinct plasmid clusters have contributed to blaKPC spread and persistence in Canada.
Sujet(s)
Infections à Klebsiella , bêta-Lactamases , Humains , Canada/épidémiologie , bêta-Lactamases/génétique , bêta-Lactamases/métabolisme , Plasmides/génétique , Protéines bactériennes/génétique , Klebsiella pneumoniae , Antibactériens/pharmacologie , Carbapénèmes/pharmacologie , Génomique , Infections à Klebsiella/épidémiologie , Tests de sensibilité microbienneRÉSUMÉ
BACKGROUND: Antimicrobial resistance threatens the ability to successfully prevent and treat infections. While hospital benchmarks regarding antimicrobial use (AMU) have been well documented among adult populations, there is less information from among paediatric inpatients. This study presents benchmark rates of antimicrobial use (AMU) for paediatric inpatients in nine Canadian acute-care hospitals. METHODS: Acute-care hospitals participating in the Canadian Nosocomial Infection Surveillance Program submitted annual AMU data from paediatric inpatients from 2017 and 2018. All systemic antimicrobials were included. Data were available for neonatal intensive care units (NICUs), pediatric ICUs (PICUs), and non-ICU wards. Data were analyzed using days of therapy (DOT) per 1000 patient days (DOT/1000pd). RESULTS: Nine hospitals provided paediatric AMU data. Data from seven NICU and PICU wards were included. Overall AMU was 481 (95% CI 409-554) DOT/1000pd. There was high variability in AMU between hospitals. AMU was higher on PICU wards (784 DOT/1000pd) than on non-ICU (494 DOT/1000pd) or NICU wards (333 DOT/1000pd). On non-ICU wards, the antimicrobials with the highest use were cefazolin (66 DOT/1000pd), ceftriaxone (59 DOT/1000pd) and piperacillin-tazobactam (48 DOT/1000pd). On PICU wards, the antimicrobials with the highest use were ceftriaxone (115 DOT/1000pd), piperacillin-tazobactam (115 DOT/1000pd), and cefazolin (111 DOT/1000pd). On NICU wards, the antimicrobials with the highest use were ampicillin (102 DOT/1000pd), gentamicin/tobramycin (78 DOT/1000pd), and cefotaxime (38 DOT/1000pd). CONCLUSIONS: This study represents the largest collection of antimicrobial use data among hospitalized paediatric inpatients in Canada to date. In 2017/2018, overall AMU was 481 DOT/1000pd. National surveillance of AMU among paediatric inpatients is necessary for establishing benchmarks and informing antimicrobial stewardship efforts.
Sujet(s)
Anti-infectieux , Infection croisée , Nouveau-né , Adulte , Enfant , Humains , Infection croisée/traitement médicamenteux , Infection croisée/épidémiologie , Infection croisée/prévention et contrôle , Ceftriaxone , Patients hospitalisés , Céfazoline , Canada/épidémiologie , Hôpitaux , Pipéracilline , TazobactamRÉSUMÉ
Importance: Trends in COVID-19 severe outcomes have significant implications for the health care system and are key to informing public health measures. However, data summarizing trends in severe outcomes among patients hospitalized with COVID-19 in Canada are not well described. Objective: To describe trends in severe outcomes among patients hospitalized with COVID-19 during the first 2 years of the COVID-19 pandemic. Design, Setting, and Participants: Active prospective surveillance in this cohort study was conducted from March 15, 2020, to May 28, 2022, at a sentinel network of 155 acute care hospitals across Canada. Participants included adult (aged ≥18 years) and pediatric (aged 0-17 years) patients hospitalized with laboratory-confirmed COVID-19 at a Canadian Nosocomial Infection Surveillance Program (CNISP)-participating hospital. Exposures: COVID-19 waves, COVID-19 vaccination status, and age group. Main Outcomes and Measures: The CNISP collected weekly aggregate data on the following severe outcomes: hospitalization, admission to an intensive care unit (ICU), receipt of mechanical ventilation, receipt of extracorporeal membrane oxygenation, and all-cause in-hospital death. Results: Among 1â¯513â¯065 admissions, the proportion of adult (n = 51â¯679) and pediatric (n = 4035) patients hospitalized with laboratory-confirmed COVID-19 was highest in waves 5 and 6 of the pandemic compared with waves 1 to 4 (77.3 vs 24.7 per 1000 patient admissions). Despite this, the proportion of patients with positive test results for COVID-19 who were admitted to an ICU, received mechanical ventilation, received extracorporeal membrane oxygenation, and died were each significantly lower in waves 5 and 6 when compared with waves 1 through 4. Admission to the ICU and in-hospital all-cause death rates were significantly higher among those who were unvaccinated against COVID-19 when compared with those who were fully vaccinated (incidence rate ratio, 4.3 and 3.9, respectively) or fully vaccinated with an additional dose (incidence rate ratio, 12.2 and 15.1, respectively). Conclusions and Relevance: The findings of this cohort study of patients hospitalized with laboratory-confirmed COVID-19 suggest that COVID-19 vaccination is important to reduce the burden on the Canadian health care system as well as severe outcomes associated with COVID-19.
Sujet(s)
COVID-19 , Infection croisée , Humains , Adulte , Enfant , Adolescent , COVID-19/épidémiologie , SARS-CoV-2 , Mortalité hospitalière , Études de cohortes , Pandémies , Études prospectives , Infection croisée/épidémiologie , Vaccins contre la COVID-19 , Canada/épidémiologieRÉSUMÉ
The coronavirus disease 2019 (COVID-19) pandemic has placed significant burden on healthcare systems. We compared Clostridioides difficile infection (CDI) epidemiology before and during the pandemic across 71 hospitals participating in the Canadian Nosocomial Infection Surveillance Program. Using an interrupted time series analysis, we showed that CDI rates significantly increased during the COVID-19 pandemic.
Sujet(s)
COVID-19 , Infections à Clostridium , Infection croisée , Humains , COVID-19/épidémiologie , Pandémies , Canada/épidémiologie , Infections à Clostridium/épidémiologie , Infection croisée/épidémiologie , HôpitauxRÉSUMÉ
Background: Invasive group A streptococcal disease (iGAS) is caused by Streptococcus pyogenes group A bacteria. In 2022, multiple disease alerts for iGAS in the Island Health region, in the context of increased infections in the paediatric population in Europe and the United States, prompted further investigation into local trends. This surveillance study summarizes epidemiological trends of iGAS in the region covered by Island Health, a regional health authority in British Columbia, in 2022. Methods: In British Columbia, iGAS is a reportable disease; all confirmed cases are reported to the regional authority and the provincial health authority (BC Centre for Disease Control). Island Health's iGAS surveillance system is passive and collects information on cases that are identified through laboratory testing. Surveillance data were summarized for 2022 and compared with historical data from 2017-2021. Results: In 2022, the incidence rate was 11.4 cases per 100,000 population (n=101), the highest observed rate in the last six years. The median age of cases was 53 years, with a range of 0-96 years, and 64% of cases were male. The highest risk of infection was reported in men 40-59 years of age, with an incidence rate of 21.3 cases per 100,000 population. The most common emm types were emm92 (n=14), emm49 (n=13), and emm83 (n=12). Overall, 85% (n=86) of cases were hospitalized, 21% (n=21) were admitted to the intensive care unit, and 6% (n=6) died. Conclusion: This study highlights that the incidence of iGAS in the Island Health region continued to increase throughout the coronavirus disease 2019 (COVID-19) pandemic, reaching its highest annual rate in 2022. In contrast to reports from Europe and the United States, there was no notable increase in infections in the paediatric population. Given the sustained increase in iGAS activity, continued monitoring and description of the epidemiology of these cases on a regular basis is imperative.
RÉSUMÉ
Background: Recent studies have demonstrated the effectiveness of nirmatrelvir-ritonavir in reducing the risk of progression to severe disease among outpatients with mild to moderate coronavirus disease 2019 (COVID-19); however, data are limited regarding the use and role of nirmatrelvir-ritonavir among hospitalized patients. This study describes the use and outcomes of nirmatrelvir-ritonavir among adults hospitalized with COVID-19 in a sentinel network of Canadian acute care hospitals during the Omicron variant phase of the pandemic. Methods: The Canadian Nosocomial Infection Surveillance Program conducts surveillance of hospitalized patients with COVID-19 in acute care hospitals across Canada. Demographic, clinical, treatment and 30-day outcome data were collected by chart review by trained infection control professionals using standardized questionnaires. Results: From January 1 to December 31, 2022, 13% (n=490/3,731) of adult patients (18 years of age and older) hospitalized with COVID-19 in 40 acute care hospitals received nirmatrelvir-ritonavir either at admission or during hospitalization. Most inpatients who received nirmatrelvir-ritonavir, 79% of whom were fully vaccinated, had at least one pre-existing comorbidity (97%) and were of advanced age (median=79 years). Few were admitted to an intensive care unit (2.3%) and among the 490 nirmatrelvir-ritonavir treated inpatients, there were 13 (2.7%) deaths attributable to COVID-19. Conclusion: These findings from a large sentinel network of Canadian acute-care hospitals suggest that nirmatrelvir-ritonavir is being used to treat adult COVID-19 patients at admission who are at risk of progression to severe disease or those who acquired COVID-19 in hospital. Additional research on the efficacy and indications for nirmatrelvir-ritonavir use in hospitalized patients is warranted to inform future policies and guidelines.
RÉSUMÉ
We investigated epidemiologic and molecular characteristics of healthcare-associated (HA) and community-associated (CA) Clostridioides difficile infection (CDI) among adult patients in Canadian Nosocomial Infection Surveillance Program hospitals during 2015-2019. The study encompassed 18,455 CDI cases, 13,735 (74.4%) HA and 4,720 (25.6%) CA. During 2015-2019, HA CDI rates decreased by 23.8%, whereas CA decreased by 18.8%. HA CDI was significantly associated with increased 30-day all-cause mortality as compared with CA CDI (p<0.01). Of 2,506 isolates analyzed, the most common ribotypes (RTs) were RT027, RT106, RT014, and RT020. RT027 was more often associated with CDI-attributable death than was non-RT027, regardless of acquisition type. Overall resistance C. difficile rates were similar for all drugs tested except moxifloxacin. Adult HA and CA CDI rates have declined, coinciding with changes in prevalence of RT027 and RT106. Infection prevention and control and continued national surveillance are integral to clarifying CDI epidemiology, investigation, and control.
Sujet(s)
Clostridioides difficile , Infections à Clostridium , Infection croisée , Adulte , Canada/épidémiologie , Clostridioides difficile/génétique , Infections à Clostridium/traitement médicamenteux , Infections à Clostridium/épidémiologie , Infection croisée/épidémiologie , Prestations des soins de santé , Humains , Tests de sensibilité microbienne , RibotypageRÉSUMÉ
BACKGROUND: Antimicrobial resistance is a growing threat to the world's ability to prevent and treat infections. Links between quantitative antibiotic use and the emergence of bacterial resistance are well documented. This study presents benchmark antimicrobial use (AMU) rates for inpatient adult populations in acute-care hospitals across Canada. METHODS: In this retrospective surveillance study, acute-care adult hospitals participating in the Canadian Nosocomial Infection Surveillance Program (CNISP) submitted annual AMU data on all systemic antimicrobials from 2009 to 2016. Information specific to intensive care units (ICUs) and non-ICU wards were available for 2014-2016. Data were analyzed using defined daily doses (DDD) per 1000 patient days (DDD/1000pd). RESULTS: Between 2009 and 2016, 16-18 CNISP adult hospitals participated each year and provided their AMU data (22 hospitals participated in ≥1 year of surveillance; 11 in all years). From 2009 to 2016, there was a significant reduction in use (12%) (from 654 to 573 DDD/1000pd, p = 0.03). Fluoroquinolones accounted for the majority of this decrease (47% reduction in combined oral and intravenous use, from 129 to 68 DDD/1000pd, p < 0.002). The top five antimicrobials used in 2016 were cefazolin (78 DDD/1000pd), piperacillin-tazobactam (53 DDD/1000pd), ceftriaxone (49 DDD/1000pd), vancomycin (combined oral and intravenous use was 44 DDD/1000pd; 7% of vancomycin use was oral), and ciprofloxacin (combined oral and intravenous use: 42 DDD/1000pd). Among the top 10 antimicrobials used in 2016, ciprofloxacin and metronidazole use decreased significantly between 2009 and 2016 by 46% (p = 0.002) and 26% (p = 0.002) respectively. Ceftriaxone (85% increase, p = 0.0008) and oral amoxicillin-clavulanate (140% increase, p < 0.0001) use increased significantly but contributed only a small component (8.6 and 5.0%, respectively) of overall use. CONCLUSIONS: This study represents the largest collection of dispensed antimicrobial use data among inpatients in Canada to date. Between 2009 and 2016, there was a significant 12% decrease in AMU, driven primarily by a 47% decrease in fluoroquinolone use. Modest absolute increases in parenteral ceftriaxone and oral amoxicillin-clavulanate use were noted but contributed a small amount of total AMU. Ongoing national surveillance is crucial for establishing benchmarks and antimicrobial stewardship guidelines.
Sujet(s)
Gestion responsable des antimicrobiens , Infection croisée/traitement médicamenteux , Résistance aux substances , Association amoxicilline-clavulanate de potassium/usage thérapeutique , Antibactériens/usage thérapeutique , Infections bactériennes/traitement médicamenteux , Canada , Ceftriaxone/usage thérapeutique , Fluoroquinolones/usage thérapeutique , Hôpitaux , Humains , Patients hospitalisés , Études rétrospectivesRÉSUMÉ
Objectives: Globally there is an increased prevalence of carbapenem-resistant Acinetobacter spp. (CRAs) and carbapenemase-producing Acinetobacter spp. (CPAs) in the hospital setting. This increase prompted the Canadian Nosocomial Infection Surveillance Program (CNISP) to conduct surveillance of CRA colonizations and infections identified from patients in CNISP-participating hospitals between 2010 and 2016. Methods: Participating acute care facilities across Canada submitted CRAs from 1 January 2010 to 31 December 2016. Patient data were collected from medical records using a standardized questionnaire. WGS was conducted on all CRAs and data underwent single nucleotide variant analysis, resistance gene detection and MLST. Results: The 7 year incidence rate of CRA was 0.02 per 10â000 patient days and 0.015 per 1000 admissions, with no significant increase observed over the surveillance period (P > 0.73). Ninety-four CRA isolates were collected from 58 hospitals, of which 93 (98.9%) were CPA. Carbapenemase OXA-235 group (48.4%) was the most common due to two separate clusters, followed by the OXA-23 group (41.9%). Patients with a travel history were associated with 38.8% of CRA cases. The all-cause 30 day mortality rate for infected cases was 24.4 per 100 CRA cases. Colistin was the most active antimicrobial agent (95.8% susceptibility). Conclusions: CRA remains uncommon in Canadian hospitals and the incidence did not increase from 2010 to 2016. Almost half of the cases were from two clusters harbouring OXA-235-group enzymes. Previous medical treatment during travel outside of Canada was common.
Sujet(s)
Infections à Acinetobacter/épidémiologie , Acinetobacter baumannii/isolement et purification , Infection croisée/épidémiologie , Surveillance épidémiologique , Hôpitaux/statistiques et données numériques , Infections à Acinetobacter/microbiologie , Acinetobacter baumannii/effets des médicaments et des substances chimiques , Acinetobacter baumannii/enzymologie , Adolescent , Adulte , Sujet âgé , Antibactériens/pharmacologie , Protéines bactériennes/génétique , Canada/épidémiologie , Carbapénèmes/pharmacologie , Enfant , Enfant d'âge préscolaire , Infection croisée/microbiologie , Résistance bactérienne aux médicaments/génétique , Femelle , Humains , Nourrisson , Nouveau-né , Mâle , Tests de sensibilité microbienne , Adulte d'âge moyen , Jeune adulte , bêta-Lactamases/génétiqueRÉSUMÉ
BACKGROUND: The clinical and molecular epidemiology of health care-associated Clostridium difficile infection in nonepidemic settings across Canada has evolved since the first report of the virulent North American pulsed-field gel electrophoresis type 1 (NAP1) strain more than 15 years ago. The objective of this national, multicentre study was to describe the evolving epidemiology and molecular characteristics of health care-associated C. difficile infection in Canada during a post-NAP1-epidemic period, particularly patient outcomes associated with the NAP1 strain. METHODS: Adult inpatients with C. difficile infection were prospectively identified, using a standard definition, between 2009 and 2015 through the Canadian Nosocomial Infection Surveillance Program (CNISP), a network of 64 acute care hospitals. Patient demographic characteristics, severity of infection and outcomes were reviewed. Molecular testing was performed on isolates, and strain types were analyzed against outcomes and epidemiologic trends. RESULTS: Over a 7-year period, 20 623 adult patients admitted to hospital with health care-associated C. difficile infection were reported to CNISP, and microbiological data were available for 2690 patients. From 2009 to 2015, the national rate of health care-associated C. difficile infection decreased from 5.9 to 4.3 per 10 000 patient-days. NAP1 remained the dominant strain type, but infection with this strain has significantly decreased over time, followed by an increasing trend of infection with NAP4 and NAP11 strains. The NAP1 strain was significantly associated with a higher rate of death attributable to C. difficile infection compared with non-NAP1 strains (odds ratio 1.91, 95% confidence interval [CI] 1.29-2.82). Isolates were universally susceptible to metronidazole; one was nonsusceptible to vancomycin. The proportion of NAP1 strains within individual centres predicted their rates of health care-associated C. difficile infection; for every 10% increase in the proportion of NAP1 strains, the rate of health care-associated C. difficile infection increased by 3.3% (95% CI 1.7%-4.9%). INTERPRETATION: Rates of health care-associated C. difficile infection have decreased across Canada. In nonepidemic settings, NAP4 has emerged as a common strain type, but NAP1, although decreasing, continues to be the predominant circulating strain and remains significantly associated with higher attributable mortality.
Sujet(s)
Infections à Clostridium/épidémiologie , Infection croisée/épidémiologie , Adolescent , Adulte , Sujet âgé , Antibactériens/usage thérapeutique , Canada/épidémiologie , Clostridioides difficile/classification , Clostridioides difficile/isolement et purification , Infections à Clostridium/traitement médicamenteux , Infections à Clostridium/mortalité , Infection croisée/traitement médicamenteux , Infection croisée/mortalité , Résistance microbienne aux médicaments , Électrophorèse en champ pulsé , Femelle , Humains , Mâle , Métronidazole/usage thérapeutique , Adulte d'âge moyen , Études rétrospectives , Résultat thérapeutique , Vancomycine/usage thérapeutique , Jeune adulteRÉSUMÉ
Carbapenemase-producing Enterobacteriaceae (CPE) are increasing globally; here we report on the investigation of CPE in Canada over a 5-year period. Participating acute care facilities across Canada submitted carbapenem-nonsusceptible Enterobacteriaceae from 1 January 2010 to 31 December 2014 to the National Microbiology Laboratory. All CPE were characterized by antimicrobial susceptibilities, pulsed-field gel electrophoresis, multilocus sequence typing, and plasmid restriction fragment length polymorphism analysis and had patient data collected using a standard questionnaire. The 5-year incidence rate of CPE was 0.09 per 10,000 patient days and 0.07 per 1,000 admissions. There were a total of 261 CPE isolated from 238 patients in 58 hospitals during the study period. blaKPC-3 (64.8%) and blaNDM-1 (17.6%) represented the highest proportion of carbapenemase genes detected in Canadian isolates. Patients who had a history of medical attention during international travel accounted for 21% of CPE cases. The hospital 30-day all-cause mortality rate for the 5-year surveillance period was 17.1 per 100 CPE cases. No significant increase in the occurrence of CPE was observed from 2010 to 2014. Nosocomial transmission of CPE, as well as international health care, is driving its persistence within Canada.
Sujet(s)
Protéines bactériennes/génétique , Infection croisée/épidémiologie , Infections à Enterobacteriaceae/épidémiologie , Enterobacteriaceae/effets des médicaments et des substances chimiques , Plasmides/métabolisme , Résistance aux bêta-lactamines/génétique , bêta-Lactamases/génétique , Adolescent , Adulte , Sujet âgé , Antibactériens/pharmacologie , Protéines bactériennes/métabolisme , Canada/épidémiologie , Carbapénèmes/pharmacologie , Enfant , Enfant d'âge préscolaire , Infection croisée/traitement médicamenteux , Infection croisée/microbiologie , Infection croisée/mortalité , Électrophorèse en champ pulsé , Enterobacteriaceae/classification , Enterobacteriaceae/génétique , Enterobacteriaceae/isolement et purification , Infections à Enterobacteriaceae/traitement médicamenteux , Infections à Enterobacteriaceae/microbiologie , Infections à Enterobacteriaceae/mortalité , Femelle , Expression des gènes , Hôpitaux , Humains , Nourrisson , Nouveau-né , Mâle , Adulte d'âge moyen , Typage par séquençage multilocus , Plasmides/composition chimique , Polymorphisme de restriction , Prévalence , Surveillance de la santé publique , Analyse de survie , Voyage/statistiques et données numériques , bêta-Lactamases/métabolismeRÉSUMÉ
Background. Clostridium difficile is a major cause of gastrointestinal illness. Epidemic NAP1 strains contain toxins A and B, a deletion in repressor tcdC, and a binary toxin. Objectives. To determine the molecular epidemiology of C. difficile in British Columbia and compare between two time points in one region. Methods. C. difficile isolates from hospital and community laboratories (2008) and one Island Health hospital laboratory (2013) were characterized by pulsed-field gel electrophoresis, PCR-ribotyping, toxin possession, tcdC genotype, and antimicrobial susceptibility. Results. In 2008, 42.7% of isolates had NAP1 designation. Hospital-collected isolates were associated with older patients and more NAP1 types. Unlike other isolates, most NAP1 isolates possessed binary toxin and a 19 bp loss in tcdC. All isolates were susceptible to metronidazole and vancomycin. A 2013 follow-up revealed a 28.9% decrease in NAP1 isolates and 20.0% increase in isolates without NAP designation in one region. Then, community-associated cases were seen in younger patients, while NAP types were evenly distributed. Isolates without NAP designation did not cluster with a PFGE pattern or ribotype. Conclusions. Evaluation of C. difficile infections within British Columbia revealed demographic associations, epidemiological shifts, and characteristics of strain types. Continuous surveillance of C. difficile will enable detection of emerging strains.
RÉSUMÉ
QUALITY ISSUE: Infectious disease outbreaks result in substantial inconvenience to patients and disruption of clinical activity. INITIAL ASSESSMENT: Between 1 April 2008 and 31 March 2009, the Vancouver Island Health Authority (Island Health) declared 16 outbreaks of Vancomycin Resistant Enterococci and Clostridium difficile in acute care facilities. As a result, infection prevention and control became one of Island Health's highest priorities. CHOICE OF SOLUTION: Quality improvement methodology, which promotes a culture of co-production between front-line staff, physicians and Infection Control Practitioners, was used to develop and test a bundle of changes in practices. IMPLEMENTATION: A series of rapid Plan-Do-Study-Act cycles, specific to decreasing hospital-acquired infections, were undertaken by a community hospital, selected for its size, clinical specialty representation, and enthusiasm amongst staff and physicians for innovation and change. Positive results were incorporated into practice at the test site, and then introduced throughout the rest of the Health Authority. EVALUATION: The changes implemented as a result of this study have enabled better control of antibiotic resistant organisms and have minimized disruption to routine activity, as well as saving an estimated $6.5 million per annum. When outbreaks do occur, they are now controlled much more promptly, even in existing older facilities. LESSONS LEARNED: Through this process, we have changed our approach in Infection Prevention and Control (IPAC) from a rules-based approach to one that is risk-based, focusing attention on identifying and managing high-risk situations.
Sujet(s)
Infection croisée/prévention et contrôle , Prévention des infections/organisation et administration , Amélioration de la qualité/organisation et administration , Clostridioides difficile , Infection croisée/épidémiologie , Épidémies de maladies , Entérocolite pseudomembraneuse/épidémiologie , Entérocolite pseudomembraneuse/prévention et contrôle , Infections bactériennes à Gram positif/épidémiologie , Infections bactériennes à Gram positif/prévention et contrôle , Humains , Prévention des infections/normes , Staphylococcus aureus résistant à la méticilline , Culture organisationnelle , Admission du patient/statistiques et données numériques , Mise au point de programmes , Évaluation de programme , Amélioration de la qualité/normes , Infections à staphylocoques/épidémiologie , Infections à staphylocoques/prévention et contrôle , Entérocoques résistants à la vancomycineRÉSUMÉ
BACKGROUND: Following a Clostridium difficile infection outbreak, the Infection Prevention and Control team at our institution queried the risk of transmission via bedpans reprocessed in washer disinfectors (WDs). This study's objective was to determine the effectiveness of the mechanical action, detergent, and temperature on the eradication of C difficile spores in 1 type of WD model. MATERIALS AND METHODS: Three types of reusable bedpans/pots were inoculated with sterile human feces that contained 1 × 10(7) CFU/mL C difficile spores. The 0.3 mL fecal-spore suspension was inoculated in sealed cryovials. These items were reprocessed using the longest wash cycle of WDs in 9 clinical units, and then tested for residual C difficile spores. The number of colonies on each replicate organism detection and counting plate was recorded after anaerobic incubation at 35°C for 48 hours, and the log reduction was calculated. RESULTS: All 9 WDs met the manufacturer's operational specifications. Forty-three (96%) of 45 bedpans had no viable spores (>5.9 log10C difficile spore reduction). Two bedpans had 1 to 2 spores remaining. Viable C difficile spores were isolated from all 9 cryovials. DISCUSSION AND CONCLUSIONS: Results demonstrated that when operating the WD as stipulated, C difficile spores were satisfactorily eliminated from bedpan surfaces. Temperature alone was insufficient to kill C difficile spores. It also suggested the importance of staff training, machine maintenance, and WD purchase specifications.
Sujet(s)
Équipement sanitaire/microbiologie , Clostridioides difficile/isolement et purification , Désinfection/méthodes , Spores/isolement et purification , Établissements de santé , Humains , Reproductibilité des résultats , TempératureRÉSUMÉ
Carbapenemase-producing organisms (CPOs) are a serious emerging problem for health care facilities worldwide. Owing to their resistance to most antimicrobial therapies, CPOs are difficult to treat and pose a challenge for infection prevention and control. Since 2010, lab-based surveillance for CPOs and PCR-based testing were implemented in British Columbia (BC), Canada. A review of CPOs in BC from 2008 to March 2014 was done to characterize the resistance mechanisms and possible clonal strain transmission and to compare pulsed-field gel electrophoresis (PFGE), multilocus sequence typing (MLST), and plasmid restriction fragment length polymorphism (RFLP) as molecular typing tools. During this study period, a total of 177 CPO cases were identified. Patient demographics and travel history were reviewed, and a descriptive analysis was carried out. PFGE profiles, MLST, and plasmid RFLP analysis for a subset of Escherichia coli, Klebsiella pneumoniae, and Enterobacter species isolates were obtained and analyzed. Our findings demonstrate that CPOs have been increasing in number in BC over time, from 1 isolate/year retrospectively identified in 2008 and 2009 to 82 isolates in 2013 and 30 isolates in the first quarter of 2014. Overall, K. pneumoniae isolates lack clonality, although some seemingly related clusters have been found. Plasmid analysis showed evidence of the spread of plasmids carrying carbapenemase-encoding genes between the examined isolates. Analysis of Enterobacter cloacae isolates revealed a more clonal nature of these CPOs in BC. The presence of related clusters provides evidence of interpatient organism transmission both within and between institutions. Although in our study, NDM-harboring E. cloacae isolates appeared to spread clonally, the spread of carbapenem resistance in K. pneumoniae seems to be plasmid mediated.
Sujet(s)
Bactéries/classification , Bactéries/génétique , Infections bactériennes/épidémiologie , Infections bactériennes/microbiologie , Protéines bactériennes/génétique , Génotype , bêta-Lactamases/génétique , Infections bactériennes/histoire , Protéines bactériennes/biosynthèse , Colombie-Britannique/épidémiologie , Analyse de regroupements , Électrophorèse en champ pulsé , Escherichia coli/classification , Escherichia coli/génétique , Histoire du 21ème siècle , Humains , Klebsiella pneumoniae/classification , Klebsiella pneumoniae/génétique , Typage par séquençage multilocus , bêta-Lactamases/biosynthèseRÉSUMÉ
Polyphasic taxonomic analysis was performed on a clinical isolate (NML 06-3099T) from a cystic fibrosis patient, including whole-genome sequencing, proteomics, phenotypic testing, electron microscopy, chemotaxonomy and a clinical investigation. Comparative whole-genome sequence analysis and multilocus sequence analysis (MLSA) between Tatumella ptyseos ATCC 33301T and clinical isolate NML 06-3099T suggested that the clinical isolate was closely related to, but distinct from, the species T. ptyseos. By 16S rRNA gene sequencing, the clinical isolate shared 98.7 % sequence identity with T. ptyseos ATCC 33301T. A concatenate of six MLSA loci (totalling 4500 bp) revealed < 93.9 % identity between T. ptyseos ATCC 33301T, other members of the genus and the clinical isolate. A whole-genome sequence comparison between NML 06-3099T and ATCC 33301T determined that the average nucleotide identity was 76.24 %. The overall DNA G+C content of NML 06-3099T was 51.27 %, consistent with members of the genus Tatumella. By matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS analysis, NML 06-3099T had a genus-level match, but not a species-level match, to T. ptyseos. By shotgun proteomics, T. ptyseos ATCC 33301T and NML 06-3099T were found to have unique proteomes. The two strains had similar morphologies and multiple fimbriae, as observed by transmission electron microscopy, but were distinguishable by phenotypic testing. Cellular fatty acids found were typical for members of the Enterobacteriaceae. NML 06-3099T was susceptible to commonly used antibiotics. Based on these data, NML 06-3099T represents a novel species in the genus Tatumella, for which the name Tatumella saanichensis sp. nov. is proposed (type strain NML 06-3099T = CCUG 55408T = DSM 19846T).
Sujet(s)
Mucoviscidose/microbiologie , Enterobacteriaceae/classification , Phylogenèse , Adolescent , Techniques de typage bactérien , Composition en bases nucléiques , Colombie-Britannique , ADN bactérien/génétique , Enterobacteriaceae/génétique , Enterobacteriaceae/isolement et purification , Acides gras/composition chimique , Humains , Mâle , Données de séquences moléculaires , Typage par séquençage multilocus , Hybridation d'acides nucléiques/génétique , ARN ribosomique 16S/génétique , Analyse de séquence d'ADN , Spectrométrie de masse MALDI , Expectoration/microbiologieRÉSUMÉ
BACKGROUND: Cryptococcus gattii (Cg) infection emerged in British Columbia in 1999. A longitudinal, clinical description of patients has not been reported. METHODS: Medical records were reviewed for Cg patients identified through surveillance (1999-2007). Risk factors for Cg mortality were explored using multivariate Cox regression; longitudinal patterns in serum cryptococcal antigen (SCrAg) titers and the probability of chest cryptococcomas over time were estimated using cubic B-splines in mixed-effects regression models. RESULTS: Among 152 patients, 111 (73.0%) were culture confirmed. Isolated lung infection was present in 105 (69.1%) patients; 47 (30.9%) had central nervous system infection, with or without lung involvement. Malignancy was the provisional diagnosis in 64 (42.1%) patients. Underlying diseases were present in 91 (59.9%) patients; 23 (15.1%) were immunocompromised, and 23 (15.1%) had asymptomatic disease. There were only 2 (1.8%) culture positive relapses, both within 12 months of follow-up. The estimated median time to resolution of lung cryptococcomas and decline in SCrAg titer to <1:8 was 2.8 and 2.9 years, respectively. Cg-related and all-cause mortality among culture-confirmed cases at 12 months' follow-up was 23.3% and 27.2%, respectively. Cg-related mortality was associated with age >50 years (hazard ratio [HR], 15.6; 95% confidence interval [CI], 1.9-130.5) and immunocompromise (HR, 5.8; CI, 1.5-21.6). All Cg-related mortality occurred among culture-positive cases within 1 year of diagnosis. CONCLUSIONS: Cryptococcomas and serum antigenemia were slow to resolve. However, late onset of failed therapy or relapse was uncommon, suggesting that delayed resolution of these findings does not require prolongation of treatment beyond that recommended by guidelines.
Sujet(s)
Cryptococcose/épidémiologie , Cryptococcus gattii , Poumon/parasitologie , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Antigènes fongiques/sang , Colombie-Britannique/épidémiologie , Enfant , Enfant d'âge préscolaire , Cryptococcose/diagnostic , Cryptococcose/traitement médicamenteux , Cryptococcose/microbiologie , Cryptococcose/mortalité , Cryptococcus gattii/isolement et purification , Cryptococcus gattii/pathogénicité , Femelle , Humains , Sujet immunodéprimé , Études longitudinales , Poumon/imagerie diagnostique , Mycoses pulmonaires/traitement médicamenteux , Mycoses pulmonaires/épidémiologie , Mycoses pulmonaires/microbiologie , Mycoses pulmonaires/mortalité , Mâle , Adulte d'âge moyen , Radiographie , Récidive , Analyse de régression , Facteurs de risque , Facteurs temps , Jeune adulteRÉSUMÉ
The usefulness of carbapenems for gram-negative infections is becoming compromised by organisms harboring carbapenemases, enzymes which can hydrolyze the drug. Currently KPC (class A), NDM (class B), and OXA-48 types (class D) are the most globally widespread carbapenemases. However, among the GES-type class A extended-spectrum ß-lactamases (ESBLs) there are variants that hydrolyze carbapenems, with blaGES-5 being the most common. Two Escherichia coli and two Serratia marcescens harboring blaGES-5 on plasmids were isolated by the Canadian Nosocomial Infection Surveillance Program (CNISP) from four different patients in a single hospital over a 2-year period. Complete sequencing of the blaGES-5 plasmids indicated that all four had nearly identical backbones consisting of genes for replication, partitioning, and stability, but contained variant accessory regions consisting of mobile elements and antimicrobial resistance genes. The plasmids were of a novel replicon type, but belonged to the MOBQ1 group based on relaxase sequences, and appeared to be mobilizable, but not self-transmissible. Considering the time periods of bacterial isolation, it would appear the blaGES-5 plasmid has persisted in an environmental niche for at least 2 years in the hospital. This has implications for infection control and clinical care when it is transferred to clinically relevant gram-negative organisms.
Sujet(s)
Résistance bactérienne aux médicaments/génétique , Escherichia coli/génétique , Régulation de l'expression des gènes bactériens , Génome bactérien , Plasmides/métabolisme , Serratia marcescens/génétique , bêta-Lactamases/génétique , Sujet âgé , Sujet âgé de 80 ans ou plus , Séquence d'acides aminés , Antibactériens/pharmacologie , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme , Canada/épidémiologie , Carbapénèmes/pharmacologie , Infection croisée/traitement médicamenteux , Infection croisée/épidémiologie , Infection croisée/microbiologie , Endodeoxyribonucleases/génétique , Endodeoxyribonucleases/métabolisme , Escherichia coli/classification , Escherichia coli/enzymologie , Escherichia coli/isolement et purification , Infections à Escherichia coli/traitement médicamenteux , Infections à Escherichia coli/épidémiologie , Infections à Escherichia coli/microbiologie , Femelle , Hôpitaux , Humains , Séquences répétées dispersées , Mâle , Adulte d'âge moyen , Données de séquences moléculaires , Phylogenèse , Plasmides/composition chimique , Réplicon , Alignement de séquences , Analyse de séquence d'ADN , Infections à Serratia/traitement médicamenteux , Infections à Serratia/épidémiologie , Infections à Serratia/microbiologie , Serratia marcescens/classification , Serratia marcescens/enzymologie , Serratia marcescens/isolement et purification , bêta-Lactamases/métabolismeRÉSUMÉ
BACKGROUND: Clostridium difficile is an anaerobic, Gram-positive bacterium that has been implicated as the leading cause of antibiotic-associated diarrhea. Metronidazole is currently the first-line treatment for mild to moderate C. difficile infections. Our laboratory isolated a strain of C. difficile with a stable resistance phenotype to metronidazole. A shotgun proteomics approach was used to compare differences in the proteomes of metronidazole-resistant and -susceptible isolates. METHODOLOGY/PRINCIPAL FINDINGS: NAP1 C. difficile strains CD26A54_R (Met-resistant), CD26A54_S (reduced- susceptibility), and VLOO13 (Met-susceptible) were grown to mid-log phase, and spiked with metronidazole at concentrations 2 doubling dilutions below the MIC. Peptides from each sample were labeled with iTRAQ and subjected to 2D-LC-MS/MS analysis. In the absence of metronidazole, higher expression was observed of some proteins in C. difficile strains CD26A54_S and CD26A54_R that may be involved with reduced susceptibility or resistance to metronidazole, including DNA repair proteins, putative nitroreductases, and the ferric uptake regulator (Fur). After treatment with metronidazole, moderate increases were seen in the expression of stress-related proteins in all strains. A moderate increase was also observed in the expression of the DNA repair protein RecA in CD26A54_R. CONCLUSIONS/SIGNIFICANCE: This study provided an in-depth proteomic analysis of a stable, metronidazole-resistant C. difficile isolate. The results suggested that a multi-factorial response may be associated with high level metronidazole-resistance in C. difficile, including the possible roles of altered iron metabolism and/or DNA repair.
Sujet(s)
Anti-infectieux/pharmacologie , Protéines bactériennes/métabolisme , Clostridioides difficile/effets des médicaments et des substances chimiques , Clostridioides difficile/métabolisme , Résistance bactérienne aux médicaments , Métronidazole/pharmacologie , Protéome , Protéines bactériennes/génétique , Chromatographie en phase liquide , Clostridioides difficile/génétique , Analyse de regroupements , Régulation de l'expression des gènes bactériens , Humains , Protéomique , Spectrométrie de masse en tandemRÉSUMÉ
BACKGROUND: Clostridium difficile are gram-positive, spore forming anaerobic bacteria that are the leading cause of healthcare-associated diarrhea, usually associated with antibiotic usage. Metronidazole is currently the first-line treatment for mild to moderate C. difficile diarrhea however recurrence occurs at rates of 15-35%. There are few reports of C. difficile metronidazole resistance in the literature, and when observed, the phenotype has been transient and lost after storage or exposure of the bacteria to freeze/thaw cycles. Owing to the unstable nature of the resistance phenotype in the laboratory, clinical significance and understanding of the resistance mechanisms is lacking. METHODOLOGY/PRINCIPAL FINDINGS: Genotypic and phenotypic characterization was performed on a metronidazole resistant clinical isolate of C. difficile. Whole-genome sequencing was used to identify potential genetic contributions to the phenotypic variation observed with molecular and bacteriological techniques. Phenotypic observations of the metronidazole resistant strain revealed aberrant growth in broth and elongated cell morphology relative to a metronidazole-susceptible, wild type NAP1 strain. Comparative genomic analysis revealed single nucleotide polymorphism (SNP) level variation within genes affecting core metabolic pathways such as electron transport, iron utilization and energy production. CONCLUSIONS/SIGNIFICANCE: This is the first characterization of stable, metronidazole resistance in a C. difficile isolate. The study provides an in-depth genomic and phenotypic analysis of this strain and provides a foundation for future studies to elucidate mechanisms conferring metronidazole resistance in C. difficile that have not been previously described.